

2017 年临床肿瘤学新进展学术研讨会——

Best of ASCO® China 2017

会议日程(Program)

会议第一天 2017 年 7 月 7 日 (Day 1, July 7, 2017)

8:00-8:15 开幕式 (Opening ceremony)

大会主席: 吴一龙(Yi-Long Wu)、 秦叔逵(Shu-Kui Qin)

CSCO 开幕致辞: 秦叔逵教授(Opening speech by Prof. Shu-Kui Qin)

血液/淋巴瘤专场(Hematologic and Lymphoma Session)		
主席(Chair): 郭 晔(Ye Guo)、黄慧强(Hui-Qiang Huang)		
时间(Time)	题目(Topic)	讲者(Speaker)
8:15-8:40	Abstract 7500 First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study.	赵维莅(Wei-Li Zhao)
	Abstract 7002 Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial.	
	Abstract 7508 Autologous (auto) versus matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic (allo) hematopoietic cell transplantation (HCT) in follicular lymphoma (FL) patients (pts) with early chemoimmunotherapy failure (ECF): A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.	
8:40-9:00	专家评述(20') Discussion	黄慧强(Hui-Qiang Huang)

9:00-9:05	讨论(Q & A)	郭 晔(Ye Guo) 黄慧强(Hui-Qiang Huang)
-----------	-----------	-------------------------------------

头颈肿瘤专场(Head and Neck Cancer Session)
主席(Chair): 林桐榆(Tong-Yu Lin)、 胡超苏(Chao-Su Hu)

时间(Time)	题目(Topic)	讲者(Speaker)
----------	-----------	-------------

9:05-9:30	Abstract 6000 Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial.	李志铭(Zhi-Ming Li)
	Abstract 6002 A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT).	
	Abstract 6007 Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer.	

9:30-9:50	专家评述(20') Discussion What it may take to cure head and neck cancer?	郭 晔(Ye Guo)
-----------	---	-------------

9:50-9:55	讨论(Q & A)	林桐榆(Tong-Yu Lin) 胡超苏(Chao-Su Hu) 郭 晔(Ye Guo)
-----------	-----------	--

胃肠肿瘤专场 1 (Gastrointestinal Cancer Session 1)
主席(Chair): 李 进(Jin Li)、 沈 琳(Lin Shen)

时间(Time)	题目(Topic)	讲者(Speaker)
9:55-10:10	Abstract 4014 Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.	张小田(Xiao-Tian Zhang)
	Abstract 3507 Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer.	

10:10-10:30	专家评述(20') Discussion	黄 镜(Jing Huang)
-------------	-------------------------	-----------------

10:30-10:35	讨论(Q & A)	李 进(Jin Li) 沈 琳(Lin Shen) 黄 镜(Jing Huang)
-------------	-----------	---

胃肠肿瘤专场 2 (Gastrointestinal Cancer Session 2)

主席(Chair): 徐瑞华(Rui-Hua Xu)、 张苏展(Su-Zhan Zhang)

时间(Time)	题目(Topic)	讲者(Speaker)
10:35-11:00	LBA 1 Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.	陈 功(Gong Chen)
	Abstract 3503 Primary (1°) tumor location is an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).	
	Abstract 3505 Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer	

	(SWOG S1406).	
11:00-11:20	专家评述(20') Discussion Personalized therapy for colorectal cancer	潘宏铭(Hong-Ming Pan)
11:20-11:25	讨论(Q & A)	徐瑞华(Rui-Hua Xu) 张苏展(Su-Zhan Zhang) 潘宏铭(Hong-Ming Pan)
12:00-13:30	午餐和/或卫星会(Lunch and/or Satellite Symposium)	
前列腺肿瘤专场 (Prostate Cancer Session)		
主席(Chair): 王秀闻(Xiu-Wen Wang)、 周芳坚(Fang-Jian Zhou)		
时间(Time)	题目(Topic)	讲者(Speaker)
14:00-14:25	LBA 3 LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.	戴 波(Bo Dai)
	LBA 5003 Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).	
	Abstract 5002 A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).	
14:25-14:45	专家评述(20') Discussion When, how and why on the use of abiraterone?	姚旭东(Xu-Dong Yao)

14:45-14:50	讨论(Q & A)	王秀问(Xiu-Wen Wang) 周芳坚(Fang-Jian Zhou) 姚旭东(Xu-Dong Yao)
-------------	-----------	--

泌尿肿瘤与免疫治疗专场(Genitourinary Cancer and Immunotherapy Session)

主席(Chair): 郭 军(Jun Guo)、 王宝成(Bao-Cheng Wang)

时间(Time)	题目(Topic)	讲者(Speaker)
14:50-15:15	Abstract 4501 Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).	何志嵩(Zhi-Song He)
	Abstract 4502 Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).	
	Abstract 4507 Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).	
15:15-15:35	专家评述(20') Discussion Is immunotherapy a current standard treatment for advanced urothelial cancer	齐 隽(Jun Qi)
15:35-15:40	讨论(Q & A)	郭 军(Jun Guo) 王宝成(Bao-Cheng Wang) 齐 隽(Jun Qi)
15:40-16:00	休息(Break)	

Current Standard Practice after ASCO 2017

主席(Chair): 吴一龙(Yi-Long Wu)、 秦叔逵(Shu-Kui Qin)

时间(Time)	题目(Topic)	讲者(Speaker)
16:00-16:30	胃肠系统肿瘤研究进展	徐瑞华(Rui-Hua Xu)
16:30-17:00	泌尿系统肿瘤研究进展	郭 军(Jun Guo)
18:00-19:30	自助晚餐(Buffet Dinner)	
19:00-20:30	卫星会(Satellite Symposium)	

会议第二天 2017年7月8日 (Day 2, July 8 2017)

乳腺癌专场 1 (Breast Cancer Session 1)

主席(Chair): 徐兵河(Bing-He Xu)、 于 丁(Ding Yu)

时间(Time)	题目(Topic)	讲者(Speaker)
8:15-8:40	LBA 500 APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).	陆劲松(Jin-Song Lu)
	Abstract 504 Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer.	
	Abstract 506 Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.	
8:40-9:00	专家评述(20') Discussion	殷咏梅(Yong-Mei Yin)

	Optimal adjuvant chemotherapy! Optimal adjuvant immunotherapy?	
9:00-9:05	讨论(Q & A)	徐兵河(Bing-He Xu) 于 丁(Ding Yu) 殷咏梅(Yong-Mei Yin)
乳腺癌专场 2 (Breast Cancer Session 2)		
主席(Chair): 江泽飞(Ze-Fei Jiang)、 廖宁(Ning Liao)		
时间(Time)	题目(Topic)	讲者(Speaker)
9:05-9:30	LBA 4 OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline <i>BRCA</i> mutation (gBRCAm).	张 频(Pin Zhang)
	Abstract 1001 Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18).	
	Abstract 1000 MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy.	
9:30-9:50	专家评述(20') Discussion New target to treat breast cancer: BRCA and CDK4/6 ?	刘 健(Jian Liu)
9:50-9:55	讨论(Q & A)	江泽飞(Ze-Fei Jiang) 廖 宁(Ning Liao) 刘 健(Jian Liu)

妇科肿瘤专场 (Gynecologic Cancer Session)

主席(Chair): 吴令英(Ling-Ying Wu)、周琦(Qi Zhou)

时间(Time)	题目(Topic)	讲者(Speaker)
9:55-10:20	Abstract 5502 Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.	李 宁(Ning Li)
	Abstract 5505 A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma.	
	Abstract 5506 Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.	
10:20-10:40	专家评述(20') Discussion Optimal adjuvant therapy for advanced endometrial carcinoma	吴小华(Xiao-Hua Wu)
10:40-10:45	讨论(Q & A)	吴令英(Ling-Ying Wu) 周琦(Qi Zhou) 吴小华(Xiao-Hua Wu)

肝胆胰肿瘤专场(Hepatobiliary/Pancreatic Cancer Session)

主席(Chair): 秦叔逵(Shu-Kui Qin)、梁军(Jun Liang)

时间(Time)	题目(Topic)	讲者(Speaker)
10:45-11:10	Abstract 4001 Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).	刘秀峰(Xiu-Feng Liu)

	<p>Abstract 4006 Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.</p>	
	<p>Abstract 4007 Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma.</p>	
11:10-11:30	<p>专家评述(20') Discussion Future perspective of molecular targeted therapy for hepato-biliary cancer</p>	秦叔逵(Shu-Kui Qin)
11:30-11:35	讨论(Q & A)	秦叔逵(Shu-Kui Qin) 梁 军(Jun Liang)
12:00-13:30	午餐和/或卫星会(Lunch and/or Satellite Symposium)	
<p>肺癌专场-1 (Lung Cancer Session 1) 主席(Chair): 吴一龙(Yi-Long Wu)、程 颖(Ying Cheng)</p>		
时间(Time)	题目(Topic)	讲者(Speaker)
14:00-14:25	<p>Abstract 8500 Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-III A (N1-N2) non-small-cell lung cancer (NSCLC) with <i>EGFR</i>-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104).</p>	周 清(Qing Zhou)
	<p>Abstract 8503 Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.</p>	
	<p>LBA 8507 Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized</p>	

	phase II trial.	
14:25-14:45	专家评述(20') Discussion Should adjuvant EGFR TKI be routinely given to patient with resectable EGFR mutation positive lung cancer?	王 洁(Jie Wang)
14:45-14:50	讨论(Q & A)	吴一龙(Yi-Long Wu) 程 颖(Ying Cheng) 王 洁(Jie Wang)

肺癌专场-2 (Lung Cancer Session 2)

主席(Chair): 王绿化(Lv-Hua Wang)、 陆 舜(Shun Lu)

时间(Time)	题目(Topic)	讲者(Speaker)
14:50-15:15	LBA9007 Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.	常建华(Jiang-Hua Chang)
	LBA9008 Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.	
	Abstract 9000 Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) $\geq 50\%$ enrolled in KEYNOTE-024.	
15:15-15:35	专家评述(20') Discussion Optimal sequence in management of biomarker-selected patients with advanced NSCLC	周彩存(Cai-Cun Zhou)
15:35-15:40	讨论(Q & A)	王绿化(Lv-Hua Wang) 陆 舜(Shun Lu)

		周彩存(Cai-Cun Zhou)
15:40-16:00	休息(Break)	
Current Standard Practice after ASCO 2017		
主席(Chair): 吴一龙(Yi-Long Wu)、 秦叔逵(Shu-Kui Qin)		
时间(Time)	题目(Topic)	讲者(Speaker)
16:00-16:30	乳腺癌研究进展	江泽飞(Ze-Fei Jiang)
16:30-17:00	肺癌研究进展	周彩存(Cai-Cun Zhou)

CSCO 闭幕致辞: 吴一龙教授(Closing speech by Prof. Yi-Long Wu)